BackPhibro Animal Health Overview

Phibro Animal Health Total Current Liabilities

Phibro Animal Health's total current liabilities is $280M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$281.87M
5.77% YoYΔ $15.39M vs prior year quarter

Peer average

Loading

Phibro Animal Health Total Current Liabilities History

Loading

Phibro Animal Health vs. peers: Total Current Liabilities Comparison

Loading

Phibro Animal Health Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Phibro Animal Health (PAHC) FAQ

Phibro Animal Health's total current liabilities stands at $280M as of March 2026. That compares with $270M in the prior-year period — up 5.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Phibro Animal Health reported $280M in total current liabilities versus $270M a year earlier — a 5.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $270M in the prior-year period — up 5.8% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Phibro Animal Health's total current liabilities evolved across reporting periods, while the comparison chart places PAHC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Phibro Animal Health's reading of $280M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.